Shattuck Labs (NASDAQ:STTK) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a report published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 target price on the stock.

Several other research analysts have also commented on the company. Citigroup reduced their price target on Shattuck Labs from $10.00 to $9.00 and set a buy rating for the company in a research report on Monday, June 17th. BTIG Research lowered shares of Shattuck Labs from a buy rating to a neutral rating in a research report on Monday, June 17th. Finally, Needham & Company LLC cut their price objective on shares of Shattuck Labs from $12.00 to $8.00 and set a buy rating on the stock in a research report on Friday, June 14th.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock opened at $3.06 on Friday. The stock has a market cap of $145.50 million, a price-to-earnings ratio of -1.59 and a beta of 1.73. The firm’s 50-day moving average is $4.93 and its two-hundred day moving average is $7.76. Shattuck Labs has a 1 year low of $1.33 and a 1 year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.50 million. Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 66.23%. The company’s revenue was up 704.5% compared to the same quarter last year. On average, equities analysts expect that Shattuck Labs will post -1.56 earnings per share for the current year.

Insider Transactions at Shattuck Labs

In related news, CEO Taylor Schreiber acquired 14,400 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was purchased at an average cost of $3.47 per share, with a total value of $49,968.00. Following the transaction, the chief executive officer now directly owns 34,502 shares of the company’s stock, valued at approximately $119,721.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Trading of Shattuck Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STTK. Rhumbline Advisers acquired a new position in Shattuck Labs in the 2nd quarter worth approximately $182,000. Ritholtz Wealth Management boosted its holdings in shares of Shattuck Labs by 57.4% in the 2nd quarter. Ritholtz Wealth Management now owns 142,540 shares of the company’s stock valued at $550,000 after acquiring an additional 52,000 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in shares of Shattuck Labs by 15.0% in the second quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after acquiring an additional 78,177 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after purchasing an additional 150,340 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Shattuck Labs during the first quarter valued at $113,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.